Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma 1 Liposarcoma 1

Interventions

Cisplatin 1041 Cyclophosphamide 973 Carboplatin 954 Radiotherapy 893 Bevacizumab 847 Gemcitabine 817 pembrolizumab 759 Paclitaxel 738 Docetaxel 734 Oxaliplatin 706 Capecitabine 649 Fluorouracil 564 Rituximab 559 Nivolumab 506 Dexamethasone 487 Etoposide 468 Doxorubicin 458 Irinotecan 442 Drug Therapy 402 Leucovorin 377 Cytarabine 342 Cetuximab 340 Lenalidomide 326 Trastuzumab 323 Pemetrexed 315 durvalumab 295 Filgrastim 287 Magnetic Resonance Spectroscopy 278 Temozolomide 275 Prednisone 274

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × OTHER × Troglitazone × Clear all

NCT00003058 2017-02-13

Troglitazone in Treating Patients With Liposarcoma

Dana-Farber Cancer Institute

Phase 2 Completed

Liposarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡